Ligand Pharmaceuticals Incorporated Free Cash Flow 2009–2025
Ligand Pharmaceuticals Incorporated reported $48.91M of free cash flow for fiscal 2025. That was 48.6% lower than fiscal 2024. Compared with fiscal 2020, the change was -2.4%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $48.91M | -48.6% |
| FY 2024 | $95.23M | +106.8% |
| FY 2023 | $46.06M | -61.6% |
| FY 2022 | $119.93M | +71.2% |
| FY 2021 | $70.04M | +39.7% |
| FY 2020 | $50.13M | +257.2% |
| FY 2019 | $-31.89M | -116.5% |
| FY 2018 | $193.17M | +123.5% |
| FY 2017 | $86.41M | +46.8% |
| FY 2016 | $58.88M | +41.4% |
| FY 2015 | $41.63M | +102.5% |
| FY 2014 | $20.56M | +1.2% |
| FY 2013 | $20.31M | +4780.4% |
| FY 2012 | $-434,000 | +65.3% |
| FY 2011 | $-1.25M | +95.4% |
| FY 2010 | $-27.14M | +20.9% |
| FY 2009 | $-34.32M | — |
Source: Ligand Pharmaceuticals Incorporated SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open LGND 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Ligand Pharmaceuticals Incorporated reported $48.91M of free cash flow for fiscal 2025. That was 48.6% lower than fiscal 2024. Compared with fiscal 2020, the change was -2.4%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Ligand Pharmaceuticals Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeLigand Pharmaceuticals Incorporated — frequently asked questions
What is Ligand Pharmaceuticals Incorporated's free cash flow?
Ligand Pharmaceuticals Incorporated (LGND) reported free cash flow of $48.91M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Ligand Pharmaceuticals Incorporated's official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.